331 related articles for article (PubMed ID: 31795416)
1. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
Chang WT; Lo YC; Gao ZH; Wu SN
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory Effective Perturbations of Cilobradine (DK-AH269), A Blocker of HCN Channels, on the Amplitude and Gating of Both Hyperpolarization-Activated Cation and Delayed-Rectifier Potassium Currents.
Lu TL; Lu TJ; Wu SN
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244431
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the Synergistic Inhibition of
Liu PY; Chang WT; Wu SN
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138174
[TBL] [Abstract][Full Text] [Related]
4. Effects of Sesamin, the Major Furofuran Lignan of Sesame Oil, on the Amplitude and Gating of Voltage-Gated Na
Kuo PC; Kao ZH; Lee SW; Wu SN
Molecules; 2020 Jul; 25(13):. PubMed ID: 32635522
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Inhibition of Delayed Rectifier K+ and Voltage-Gated Na+ Currents by Artemisinin in Pituitary Tumor (GH3) Cells.
So EC; Wu SN; Wu PC; Chen HZ; Yang CJ
Cell Physiol Biochem; 2017; 41(5):2053-2066. PubMed ID: 28456794
[TBL] [Abstract][Full Text] [Related]
6. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
Beck J; Henschel C; Chou J; Lin A; Del Balzo U
Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
Yang Y; Yu X; Zhang Y; Ding G; Zhu C; Huang S; Jia Z; Zhang A
Clin Sci (Lond); 2018 Apr; 132(7):825-838. PubMed ID: 29581249
[TBL] [Abstract][Full Text] [Related]
9. Effective Perturbations of the Amplitude, Gating, and Hysteresis of
Hsiao HT; Lu GL; Liu YC; Wu SN
Membranes (Basel); 2021 Aug; 11(8):. PubMed ID: 34436399
[TBL] [Abstract][Full Text] [Related]
10. Evidence for Inhibitory Perturbations on the Amplitude, Gating, and Hysteresis of A-Type Potassium Current, Produced by Lacosamide, a Functionalized Amino Acid with Anticonvulsant Properties.
Cho HY; Chuang TH; Wu SN
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163091
[TBL] [Abstract][Full Text] [Related]
11. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Effectiveness in Concerted
So EC; Gao ZH; Ko SY; Wu SN
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31948124
[TBL] [Abstract][Full Text] [Related]
13. In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity.
Eleftheriadis T; Pissas G; Mavropoulos A; Nikolaou E; Filippidis G; Liakopoulos V; Stefanidis I
Arch Immunol Ther Exp (Warsz); 2020 Oct; 68(6):31. PubMed ID: 33011826
[TBL] [Abstract][Full Text] [Related]
14. The comprehensive electrophysiological study of curcuminoids on delayed-rectifier K
Kuo PC; Yang CJ; Lee YC; Chen PC; Liu YC; Wu SN
Eur J Pharmacol; 2018 Jan; 819():233-241. PubMed ID: 29225191
[TBL] [Abstract][Full Text] [Related]
15. The Evidence for Sparsentan-Mediated Inhibition of
Chuang TH; Cho HY; Wu SN
Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052766
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Columbianadin, a Bioactive Coumarin Derivative, in Perturbing Transient and Persistent
Chang WT; Wu SN
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435511
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.
Miao AF; Liang JX; Yao L; Han JL; Zhou LJ
Ren Fail; 2021 Dec; 43(1):803-810. PubMed ID: 33966598
[TBL] [Abstract][Full Text] [Related]
18. Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
Huang H; Wang X; Zhang X; Wang H; Jiang W
Toxicol Lett; 2020 Oct; 331():112-121. PubMed ID: 32534005
[TBL] [Abstract][Full Text] [Related]
19. Effects of midazolam on ion currents and membrane potential in differentiated motor neuron-like NSC-34 and NG108-15 cells.
So EC; Wu KC; Kao FC; Wu SN
Eur J Pharmacol; 2014 Feb; 724():152-60. PubMed ID: 24374009
[TBL] [Abstract][Full Text] [Related]
20. The Effectiveness in Activating M-Type K
Cho HY; Chuang TH; Wu SN
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
